Patents Assigned to Bristol-Myers Company
  • BU-3420T antifungal antibiotic
    Patent number: 4952572
    Abstract: The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-1 (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: November 13, 1989
    Date of Patent: August 28, 1990
    Assignee: Bristol-Myers Company
    Inventors: Hiroaki Ohkuma, Masataka Konishi, Kiyoshi Matsumoto, Toshikazu Oki, Yutaka Hoshino
  • Drug-monoclonal antibody conjugates
    Patent number: 4952394
    Abstract: There is disclosed a drug-monoclonal antibody conjugate wherein the antibody is linked to a antitumor drug using disulfide benzyl carbamate or carbonate as the linker. Also disclosed is a method of delivering an active antitumor drug to the site of tumor cells in a mammal by administering the drug-monoclonal antibody conjugate.
    Type: Grant
    Filed: November 23, 1987
    Date of Patent: August 28, 1990
    Assignee: Bristol-Myers Company
    Inventor: Peter D. Senter
  • Concentrated, stabilized cis-diamminedinitratoplatinum solutions for conversion to cisplatin
    Patent number: 4946689
    Abstract: The invention relates to chemically stable, concentrated solutions of cis-diamminedinitratoplatinum which are pH-stabilized with nitric acid and are readily convertible to parenteral cisplatin solutions by addition of sources of chloride ion.
    Type: Grant
    Filed: November 23, 1988
    Date of Patent: August 7, 1990
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, Robert K. Perrone, Joseph B. Bogardus, Kenneth W. Douglas, Sr.
  • Intermediates and process for the preparation of antihypercholesterolemic tetrazole compounds
    Patent number: 4939265
    Abstract: This invention provides novel tetrazole intermediates of the formula ##STR1## wherein R.sup.1 and R.sup.4 each are independently hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or trifluoromethyl;R.sup.2, R.sup.3, R.sup.5 and R.sup.6 each are independently hydrogen, halogen, C.sub.1-4 alkyl or C.sub.1-4 alkoxy;B is hydrogen, C.sub.1-4 alkoxycarbonyl, CH.sub.2 Y or CH.sub.2 Z;Y is hydrogen, hydroxyl or X;Z is ##STR2## X is bromo, chloro or iodo; R.sup.10 is C.sub.1-4 alkyl; andR.sup.11 is phenyl which is unsubstituted or substituted by one or two C.sub.1-4 alkyl or chloro substituents.and processes thereof which are useful for the preparation of antihypercholesterolemic agents.
    Type: Grant
    Filed: November 1, 1989
    Date of Patent: July 3, 1990
    Assignee: Bristol-Myers Company
    Inventors: John J. Wright, Sing-Yuen Sit, Neelakantan Balasubramanian, Peter J. Brown
  • Epipodophyllotoxin glucoside 4'-acyl derivatives
    Patent number: 4935504
    Abstract: Novel 4'-esters, 4'-carbonates and 4'-carbamates of 4'-demethylepipodophyllotoxin glucosides are disclosed. These agents exhibit antitumor activity in animals.
    Type: Grant
    Filed: December 2, 1988
    Date of Patent: June 19, 1990
    Assignee: Bristol-Myers Company
    Inventors: Mark G. Saulnier, Dolatrai M. Vyas, David R. Langley
  • Process for cephem prodrug esters
    Patent number: 4935508
    Abstract: A process for the selective formation of oximino o-protected derivatives of lower alkyl 2-(2-aminothiazol-4-yl)-2-oximinoacetates, and their use in the acylation of 7-amino-cephalosporin compounds is disclosed.
    Type: Grant
    Filed: August 23, 1988
    Date of Patent: June 19, 1990
    Assignee: Bristol-Myers Company
    Inventors: Hajime Kamachi, Takaaki Okita, Satsuki Okuyama, Takayuki Naito
  • Antiarthritic isoxazole-4-carboxamides
    Patent number: 4935434
    Abstract: Disclosed herein are isoxazole-4-carboxamides having the formula ##STR1## wherein R.sup.1 is C.sub.3-6 cycloalkyl and R.sup.2 is selected from the group consisting of C.sub.1-5 alkyl, C.sub.2-5 alkenyl, C.sub.2-5 alkynyl, C.sub.3-6 cycloalkyl, phenyl, and phenyl substituted with at least one group selected from C.sub.1-5 alkyl, C.sub.1-5 alkoxy, C.sub.1-5 alkylthio, and halo-substituted C.sub.1-5 alkyl; with the proviso that when R.sup.1 is cyclopropyl, R.sup.2 is not methyl, ethyl, or cyclobutyl; or R.sup.1 is C.sub.1-5 alkyl and R.sup.2 is phenylmethyl wherein the ring portion is opt. substituted with a halo-substituted C.sub.1-5 alkyl group. These compounds have antiinflammatory and antiarthritic activities and are also useful as intermediates in the preparation of .beta.-ketonitriles.
    Type: Grant
    Filed: January 26, 1988
    Date of Patent: June 19, 1990
    Assignee: Bristol-Myers Company
    Inventor: William T. Han
  • BMY-28121, a new antitumor antibiotic
    Patent number: 4935362
    Abstract: A new antitumor antibiotic designated herein as BMY-28121 is produced by fermentation of Streptomyces albus strain K7331-113 (ATCC 39897). BMY-28121, which may be recovered from the fermentation broth in either its natural free hydroxy form (BMY-28121A) or methyl ether form (BMY-28121B), inhibits gram-positive bacteria and anaerobes and inhibits the growth of mammalian tumors such as P-388 leukemia, L-1210 leukemia and B16 melanoma.
    Type: Grant
    Filed: March 30, 1987
    Date of Patent: June 19, 1990
    Assignee: Bristol-Myers Company
    Inventors: Mitsuaki Tsunakawa, Masataka Konishi, Takeo Miyaki
  • Method of treatment for melancholic depression
    Patent number: 4933343
    Abstract: Buspirone and its pharmaceutically acceptable salts are useful in the clinical improvement of major depression including melancholia.
    Type: Grant
    Filed: January 12, 1989
    Date of Patent: June 12, 1990
    Assignee: Bristol-Myers Company
    Inventors: Jerry Cott, Neil M. Kurtz, Donald S. Robinson
  • Etoposide solutions
    Patent number: 4927638
    Abstract: A solution of etoposide in dimethylisosorbide is disclosed. The solution is useful for filling gelatin capsules and may also be formulated into parenteral dosage forms.
    Type: Grant
    Filed: September 12, 1988
    Date of Patent: May 22, 1990
    Assignee: Bristol-Myers Company
    Inventors: Gururaj Bykadi, Murray A. Kaplan, Richard G. Corrao, Edward J. Bara, Ismat Ullah, Shreeram N. Agharkar
  • Chemical intermediates and process
    Patent number: 4927968
    Abstract: The present invention relates to novel intermediates of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkyl and R is ##STR2## --CH.sub.2 OH or --CH.sub.2 X in which X is a conventional leaving group and Y is lower alkyl and the use thereof in a process for the preparation of certain histamine H.sub.2 -antagonists.
    Type: Grant
    Filed: April 11, 1988
    Date of Patent: May 22, 1990
    Assignee: Bristol-Myers Company
    Inventors: Aldo A. Algieri, Robert F. Farney
  • Substituted 7-oxomitosanes
    Patent number: 4927943
    Abstract: The present invention provides novel mitomycin analogs containing a disulfide group and processes for the preparation thereof. These compounds are mitomycin A analogs in which the 7-alkoxy group bears an organic substituent incorporating a disulfide group. Mitomycin A is an antibiotic of established utility, and the 7-O-substituted mitosane analogs thereof have similar utility.
    Type: Grant
    Filed: November 7, 1988
    Date of Patent: May 22, 1990
    Assignee: Bristol-Myers Company
    Inventors: Dolatrai M. Vyas, Terrence W. Doyle, Richard A. Partyka
  • BU-3839T antibiotic
    Patent number: 4927848
    Abstract: A new antibiotic having the chromophore structure of the pluramycin family of antibiotics is produced by fermentation of Streptomyces ciolaceus ATCC 53807. The new antibiotic designated BU-3839T, exhibits potent antibacterial activity and also inhibits the growth of tumors in experimental animal systems.
    Type: Grant
    Filed: September 19, 1988
    Date of Patent: May 22, 1990
    Assignee: Bristol-Myers Company
    Inventors: Masataka Konishi, Keiko Shimizu, Masaru Ohbayashi, Koji Tomita, Takeo Miyaki, Toshikazu Oki
  • Antihypercholesterolemic nitrile compounds
    Patent number: 4927944
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each are independently hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or trifluoromethyl;A is ##STR2## and R.sup.5 is hydrogen, a hydrolyzable ester group or a cation to form a non-toxic pharmaceutically acceptable salt,are novel antihypercholesterolemic agents which inhibit cholesterol biosynthesis. Intermediates and processes for their preparation are disclosed.
    Type: Grant
    Filed: August 25, 1988
    Date of Patent: May 22, 1990
    Assignee: Bristol-Myers Company
    Inventors: Sing-Yuen Sit, John J. Wright
  • Substituted 3-cyclobutene-1,2-dione intermediates
    Patent number: 4927970
    Abstract: The present invention relates to novel intermediates of the formula ##STR1## wherein R is lower alkyl or cyclohexyl, and X is hydroxy or a conventional leaving group, and the use thereof in a process for the preparation of certain histamine H.sub.2 -antagonists.
    Type: Grant
    Filed: April 11, 1988
    Date of Patent: May 22, 1990
    Assignee: Bristol-Myers Company
    Inventors: James L. Douglas, Guy Fabre, Claude Demosthene
  • BBM-1675c and d antitumor antibiotics
    Patent number: 4921700
    Abstract: There is provided new antitumor antibiotic substances designated herein as BBM-1675C and BBM-1675D, said substances being produced by selective chemical hydrolysis of the bioactive components BBM-1675A.sub.1 (esperamicin A.sub.1) or BBM-1675A.sub.2 (esperamicin A.sub.2). The new antitumor antibiotics exhibit both antimicrobial activity and antitumor activity.
    Type: Grant
    Filed: May 28, 1987
    Date of Patent: May 1, 1990
    Assignee: Bristol-Myers Company
    Inventor: Jerzy Golik
  • Phosphorus containing derivatives of epipodophyllotoxin
    Patent number: 4916217
    Abstract: Etoposide-3',4'-quinone is converted into a phosphorane or phosphate ester by reaction with an organic phosphine or phosphite. The resulting phosphoranes and phosphates have anti-tumor activity in animals.
    Type: Grant
    Filed: January 8, 1987
    Date of Patent: April 10, 1990
    Assignee: Bristol-Myers Company
    Inventor: Mark G. Saulnier
  • BU-3420T Antitumor antibiotic
    Patent number: 4916065
    Abstract: The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-1 (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: June 10, 1988
    Date of Patent: April 10, 1990
    Assignee: Bristol-Myers Company
    Inventors: Hiroaki Ohkuma, Masataka Konishi, Kiyoshi Matsumoto, Toshikazu Oki, Yutaka Hoshino
  • BU-2867T peptide antibiotics
    Patent number: 4916063
    Abstract: Novel peptide antibiotics designated herein as BU-2867T F and G are produced by fermentation of Polyangium brachysporum strain K481-B101 (ATCCC 53080). The new antibiotics are found to have antifungal activity and to inhibit P388 lymphatic leukemia in rodents.
    Type: Grant
    Filed: September 14, 1987
    Date of Patent: April 10, 1990
    Assignee: Bristol-Myers Company
    Inventors: Masahisa Oka, Masataka Konishi
  • Fluoro-substituted epipodophyllotoxin glucosides
    Patent number: 4912204
    Abstract: The present invention provides antitumor fluoro-substituted 4'-demethylepipodophyllotoxin glucosides.
    Type: Grant
    Filed: September 6, 1988
    Date of Patent: March 27, 1990
    Assignee: Bristol-Myers Company
    Inventors: Takeshi Ohnuma, Tetsuro Yamasaki, Hideo Kamei, Takayuki Naito